US EditionIndia drugmakers to sell Ozempic copy for $14 a month as Novo patent expires
6 Articles
6 Articles
The Indian pharmaceutical companies took advantage of the expiry of the Ozempic patent, the successful medicine to lose weight and treat Novo Nordisk A/S diabetes, to launch generic versions at reduced prices in a country with the third largest overweight population.Natco Pharma Ltd. plans to manufacture a semaglutide injection, the active substance of Ozempic and Wegovy, at one of the lowest initial prices on the market: 1290 rupees ($14) per m…
India drugmakers to sell Ozempic copy for $14 a month as Novo patent expires
Indian drugmakers seized on the patent expiry for Novo Nordisk A/S’s blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the third-largest overweight population.
Ozempic copies at $14 in India as generic GLP-1 era starts
At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the third-largest overweight population. Injection pens for the weight-loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai. MUST CREDIT: Dhiraj Singh/Bloomberg Natco Pharma Ltd. plans to make an injection…
India has initiated the marketing of generic versions of semaglutide only 24 hours after the expiry of the Danish pharmaceutical company Novo Nordisk patent on this compound, which is the basis of medicines widely used to treat diabetes and promote weight loss such as Ozempic and Wegovy. The rapid reaction of the Indian pharmaceutical sector marks the beginning of a
12:00 Because the patent protection for the obesity and diabetes medications Wegovy and Ozempic is expiring, companies in India are bringing cheaper copies to the market. The Danish manufacturer Novo Nordisk is looking at...
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
